Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults

"In this randomized double-blind clinical trial of healthy adults administered CBD, 5 mg/kg/d for 28 days, 8 (5.6%) experienced liver enzyme level elevations and 7 (4.9%) met protocol defined criteria for potential DILI (Drug-Induced Liver Injury). This research has important implications for consumer safety. The findings suggest that CBD use at doses representative of currently available unregulated consumer products can lead to liver enzyme level elevations in healthy adults."

Authors: Jeffry Florian, PhD; Pablo Salcedo, MD; Keith Burkhart, MD; Aanchal Shah, MS, MBA; Lakshmi Manasa S. Chekka, PharmD, PhD; Dro Keshishi, PharmD; Vikram Patel, PhD; ShanChao Yang, PharmD; Melanie Fein, MD; Ryan DePalma, PhD; Murali Matta, PhD; David G. Strauss, MD, PhD; Rodney Rouse, PhD, DVM, MBA

Read full article on JAMA Network

Download PDF